UNMET NEEDS

. . . . . .
About Pulmonary Hypertension (PH)
Pulmonary hypertension is a severe, rare lung disease characterized by high blood pressure in the pulmonary arteries, which deliver blood from the heart to the lungs.
. . . . . .
The high pressure causes the heart to work harder to pump blood. This, in turn, causes strain that can lead to the heart becoming larger and weaker and can eventually result in right heart failure.

Pulmonary Arterial Hypertension affects more than 30,000 patients in the U.S. with an estimated five-year survival rate following diagnosis of 57%* (SEE FOOTNOTE)

. . . . . .
Respira’s RT234 drug-device product is currently in development for two PH indications:

Pulmonary Arterial Hypertension (PAH)
WHO Group 1 PH

Pulmonary arterial hypertension (PAH) is a rare, progressive, life-threatening disorder characterized by increased pressure in the pulmonary arteries that carry blood from the heart to the lungs. The increased pulmonary artery pressure strains the heart, which can limit physical activity, cause breathlessness and fatigue during activities of daily living, and can ultimately result in heart failure and reduced life expectancy. PAH affects more than 30,000 patients in the U.S. Based on data from the Registry to EValuate Early And Long-term PAH disease management (REVEAL) of patients in the U.S., the estimated five-year survival rate of PAH following diagnosis is 57%.
Pulmonary Hypertension in Interstitial Lung Disease (ILD) WHO Group 3.2 PH

Pulmonary hypertension (PH) is a common complication of interstitial lung disease (ILD), a broad group of more than 200 lung disorders that cause scarring (fibrosis) of the lungs, with substantial morbidity and mortality.

 

In the U.S., an estimated 30,000 ILD patients also have increased pulmonary arterial pressures, which can adversely affect treatment outcomes and impact health care costs. The development of PH in ILD is associated with increased exertional oxygen requirements, diminished functional capacity, and decreased life expectancy.

*Based on data from the Registry to EValuate Early And Long-term PAH disease management (REVEAL) of patients in the U.S.

Learn more about our Phase 2B clinical trial in PAH [here]

Phase 2 clinical trials of our leading pipeline candidate are underway
. . . . . .

Respira’s lead drug-device product candidate, RT234-PAH, is a first-in-class inhaled therapy intended for as-needed (PRN) use by patients experiencing symptoms. This contrasts with all other current PAH treatments, which are taken according to a chronic treatment regimen.

SEE OUR PIPELINE